Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167980 | 0.81 | CNR1 (0.35) | CNR1CNR2PIK3CDSLC6A9MAPT | |
| SCHEMBL13416610 | 0.78 | SLC6A9 (0.38) | PIK3CDSLC6A9 | |
| SCHEMBL18199163 | 0.78 | SLC6A9 (0.38) | PIK3CDSLC6A9 | |
| SCHEMBL3535268 | 0.76 | L3MBTL1 (0.38) | ALDH1A1 | |
| SCHEMBL4038087 | 0.76 | L3MBTL1 (0.38) | ALDH1A1 | |
| SCHEMBL4035789 | 0.76 | L3MBTL1 (0.38) | ALDH1A1 | |
| SCHEMBL4808864 | 0.74 | HTT (0.35) | CNR1CNR2PIK3CD | |
| SCHEMBL4597568 | 0.74 | HTT (0.35) | CNR1CNR2PIK3CD | |
| Ammonia Solution, Strong SCHEMBL9243093 | 0.74 | L3MBTL1 (0.37) | ALDH1A1 | |
| Formic Acid SCHEMBL28358042 | 0.74 | CNR1 (0.34) | CNR1CNR2SLC6A9MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CNR1 391/4885CNR2 171/4885PIK3CD 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.